Related Experiment Video

Updated: Jul 17, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

Lipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution

Lihuan Lin1, Thomas R Mitchell2, Karoline Sanches2

  • 1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia.

International Journal of Pharmaceutics
|July 15, 2026
PubMed

Upregulation of the voltage-gated potassium channel KV1.3 in effector memory T cells has been implicated in several autoimmune diseases, making selective KV1.3 blockade an attractive therapeutic strategy. HsTX1[R14A], a 34-residue peptide with picomolar potency and high selectivity for KV1.3, is effective in a rodent model of rheumatoid arthritis. However, the in vivo half-life of HsTX1[R14A] can be improved to enhance its potential as a therapeutic candidate. Here we explore how conjugation to C14, C16 or C18 acyl chains affects HsTX1[R14A] binding to serum albumin and lipoproteins, potency at KV1.3, pharmacokinetics (PK), and biodistribution to key organs, tissues, and lymph nodes. The fluorophore Cy5 was conjugated to the HsTX1[R14A] analogs for biodistribution studies. LC-MS/MS assays were developed to quantify the lipidated peptides in mouse plasma. Conjugation of palmitic and stearic acids to HsTX1[R14A] caused over 20-fold loss in potency but significantly enhanced its binding to albumin, while showing minimal association with plasma lipoproteins. This modification extended the plasma exposure by 9-fold and prolonged the elimination half-life by 2-fold after subcutaneous (SC) injection to mice. Biodistribution studies demonstrated that Cy5-labelled lipidated analogs enhanced accumulation at the dosing site and draining lymph nodes at 4 and 12 h after SC injection compared to Cy5-HsTX1[R14A]. Cy5-labelled lipidated analogs of HsTX1[R14A] also accumulated in the gastrointestinal tract more than HsTX1[R14A], while having significantly less exposure in the kidneys at 4 and 12 h after SC administration. Thus, lipidation is a promising approach to optimize the PK, biodistribution and therapeutic potential of HsTX1[R14A].

Keywords:
Albumin-bindingBiodistributionLipidationPeptide deliveryPharmacokinetics

More Related Videos

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...